Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA clears "first" molecular test for herpes

This article was originally published in Clinica

Executive Summary

The US FDA has granted 510(k) clearance for a herpes simplex virus (HSV) test developed by EraGen Biosciences. The company claims the MultiCode RTx HSV 1&2 kit is the first FDA-cleared molecular test for the virus. The PCR-based diagnostic distinguishes between HSV-1 and HSV-2 in vaginal lesion specimens from symptomatic females. This is important because HSV-2 has a higher recurrence rate, and it is one of the most common sexually transmitted diseases in the US. Madison, Wisconsin-based EraGen says that its test has "considerable advantages" over traditional testing methods for herpes, such as cell culturing and serology, which detects antibodies to the virus. This includes "excellent" sensitivity and specificity, and rapid time to result (around four hours).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT094763

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel